Women's Health & Pregnancy Clinical Trials

Statistical methods in women's health & pregnancy trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All women's health & pregnancy trials

490 results

• AMPLIFY-201Independent statistical analysis of A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 25NCT04853017
• Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment: Complete Statistical AnalysisIndependent statistical analysis of Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02317783).Phase 2Results postedn = 15NCT02317783
• An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 101NCT01574326
• An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data: Complete Statistical AnalysisIndependent statistical analysis of An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04854707).Phase NAResults postedn = 5,484NCT04854707
• Ancillary Study of the Lessening Incontinence With Low-impact Activity Study: Complete Statistical AnalysisIndependent statistical analysis of Ancillary Study of the Lessening Incontinence With Low-impact Activity Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04776720).Phase NAResults postedn = 240NCT04776720
• Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women: Complete Statistical AnalysisIndependent statistical analysis of Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 23NCT01889199
• Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1: Complete Statistical AnalysisIndependent statistical analysis of Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02574910).Phase 1Results postedn = 4NCT02574910
• Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.: Complete Statistical AnalysisIndependent statistical analysis of Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 13NCT04796324
• APAIndependent statistical analysis of Contraceptive Counseling Following an Abortion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756314).Phase NAResults postedn = 246NCT00756314
• APPOSEIndependent statistical analysis of Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 60NCT04002141
• ARIESComplete statistical analysis of the ARIES phase 3 trial of mirabegron versus placebo in patients with symptoms of overactive bladder, including trial design, ANCOVA methodology, primary and secondary endpoint results, multiplicity, missing-data…Phase 3Results postedn = 2,149NCT00662909
• Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 95NCT03648983
• AS900672-Enriched in Ovulation Induction: Complete Statistical AnalysisIndependent statistical analysis of AS900672-Enriched in Ovulation Induction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00553514).Phase 2Results postedn = 71NCT00553514
• ASCEND-PIndependent statistical analysis of Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 4NCT05682326
• ASPIRINIndependent statistical analysis of Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02409680).Phase NAResults postedn = 11,976NCT02409680
• Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 39NCT01658514
• Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 11NCT02921269
• ATNIndependent statistical analysis of Acute Renal Failure Trial Network (ATN) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00076219).Phase 3Results postedn = 1,124NCT00076219
• Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy: primary endpoint results, effect estimate…Phase 2Results postedn = 6NCT03872388
• Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists: Complete Statistical AnalysisIndependent statistical analysis of Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04196777).Phase NAResults postedn = 525NCT04196777
• AURIONIndependent statistical analysis of Aurinia Early Urinary Protein Reduction Predicts Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02949973).Phase 2Results postedn = 10NCT02949973
• Autologous Cell Therapy for Treatment of Fecal Incontinence: Complete Statistical AnalysisIndependent statistical analysis of Autologous Cell Therapy for Treatment of Fecal Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01600755).Phase 1/2Results postedn = 53NCT01600755
• Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009): Complete Statistical AnalysisIndependent statistical analysis of Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer…Phase 1Results postedn = 12NCT00562640
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 16NCT03610490
• Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 41NCT00782275
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 998NCT02718417
• Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02698891).Phase 2Results postedn = 127NCT02698891
• Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00920816).Phase 3Results postedn = 492NCT00920816
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 217NCT04579380
• BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 189NCT00117637
• Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin:…Phase 2Results postedn = 29NCT00993616
• BELLE-4Independent statistical analysis of A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation: primary endpoint results,…Phase 2/3Results postedn = 416NCT01572727
• Berinert (C1INH) vs Placebo for DGF/IRI: Complete Statistical AnalysisIndependent statistical analysis of Berinert (C1INH) vs Placebo for DGF/IRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04696146).Phase 1/2Results postedn = 45NCT04696146
• BETTERIndependent statistical analysis of Bringing Education Through Technology, Empathic Listening, and Research: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05214118).Phase NAResults postedn = 29NCT05214118
• Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 5NCT00684996
• Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 60NCT00369122
• BICARBIndependent statistical analysis of Dietary Acid Load, Kidney Function and Disability in Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02691663).Phase NAResults postedn = 196NCT02691663
• Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 11NCT04489940
• Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328): Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328): primary endpoint results, effect estimate with confidence interval,…Phase 1Results postedn = 158NCT01345786
• Bladder Scan of Residual Urine With New Catheter: Complete Statistical AnalysisIndependent statistical analysis of Bladder Scan of Residual Urine With New Catheter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01048541).Phase 2/3Results postedn = 37NCT01048541
• BLUESIndependent statistical analysis of Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05026710).Phase NAResults postedn = 224NCT05026710
• BMS 247550 to Treat Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of BMS 247550 to Treat Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00030992).Phase 2Results postedn = 102NCT00030992
• BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT): Complete Statistical AnalysisIndependent statistical analysis of BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 1NCT04296942
• Botulin-A Toxin Instillations and Overactive Bladder: Complete Statistical AnalysisIndependent statistical analysis of Botulin-A Toxin Instillations and Overactive Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00583219).Phase 1/2Results postedn = 25NCT00583219
• Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access: Complete Statistical AnalysisIndependent statistical analysis of Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 10NCT03300024
• Breast Cancer Risk Biomarkers in Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of Breast Cancer Risk Biomarkers in Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01252290).Phase 2Results postedn = 35NCT01252290
• BreastCAREIndependent statistical analysis of Breast Cancer Risk Reduction: A Patient Doctor Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01830933).Phase NAResults postedn = 1,235NCT01830933
• Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 31NCT01267253
• Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor: Complete Statistical AnalysisIndependent statistical analysis of Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01519765).Phase 4Results postedn = 73NCT01519765
• BULLETIndependent statistical analysis of BULLET: Bladder Ultrasound Limits Length (of Time), Expedites Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03860311).Phase NAResults postedn = 45NCT03860311

← All therapeutic areas